How should minimally important change (MIC) scores for the Patient Oriented Eczema Measure (POEM) be interpreted?: a validation using varied methods

Howells, Laura; Ratib, Sonia; Chalmers, J.R.; Bradshaw, Lucy; Thomas, K.S.

doi:10.1111/bjd.16367

All Outputs (5)

Temporarily quadrupling the dose of inhaled steroid to prevent asthma exacerbations: FAST (2018)
Journal Article
McKeever, T., Mortimer, K., Bradshaw, L., Haydock, R., Pavord, I., Higgins, B., …Harrison, T. (2018). Temporarily quadrupling the dose of inhaled steroid to prevent asthma exacerbations: FAST. Health Technology Assessment, 22(70), 1-82. https://doi.org/10.3310/hta22700

Development of a standardised set of metrics for monitoring site performance in multicentre randomised trials: a Delphi study (2018)
Journal Article
Whitham, D., Turzanski, J., Bradshaw, L., Clarke, M., Culliford, L., Duley, L., …Wood, J. (2018). Development of a standardised set of metrics for monitoring site performance in multicentre randomised trials: a Delphi study. Trials, 19, Article 557. https://doi.org/10.1186/s13063-018-2940-9

Background Site performance is key to the success of large multicentre randomised trials. A standardised set of clear and accessible summaries of site performance could facilitate the timely identification and resolution of potential problems, minim... Read More about Development of a standardised set of metrics for monitoring site performance in multicentre randomised trials: a Delphi study.

Follow-on RifAximin for the prevention of recurrence following standard treatment of infection with Clostridium difficile (RAPID): a randomised placebo controlled trial (2018)
Journal Article
Major, G., Bradshaw, L., Boota, N., Sprange, K., Diggle, M., Montgomery, A., …Spiller, R. (2018). Follow-on RifAximin for the prevention of recurrence following standard treatment of infection with Clostridium difficile (RAPID): a randomised placebo controlled trial. Gut, https://doi.org/10.1136/gutjnl-2018-316794

Background Clostridium difficile infection (CDI) recurs after initial treatment in approximately one in four patients. A single-centre pilot study suggested that this could be reduced using ‘follow-on’ rifaximin treatment. We aimed to assess the effi... Read More about Follow-on RifAximin for the prevention of recurrence following standard treatment of infection with Clostridium difficile (RAPID): a randomised placebo controlled trial.

Quadrupling inhaled glucocorticoid dose to abort asthma exacerbations (2018)
Journal Article
McKeever, T., Mortimer, K., Wilson, A., Walker, S., Brightling, C., Skeggs, A., …Harrison, T. (2018). Quadrupling inhaled glucocorticoid dose to abort asthma exacerbations. New England Journal of Medicine, 378(10), 902-910. https://doi.org/10.1056/NEJMoa1714257

Copyright © 2018 Massachusetts Medical Society. BACKGROUND Asthma exacerbations are frightening for patients and are occasionally fatal. We tested the concept that a plan for patients to manage their asthma (self-management plan), which included a te... Read More about Quadrupling inhaled glucocorticoid dose to abort asthma exacerbations.

How should minimally important change (MIC) scores for the Patient Oriented Eczema Measure (POEM) be interpreted?: a validation using varied methods (2018)
Journal Article
Howells, L., Ratib, S., Chalmers, J., Bradshaw, L., & Thomas, K. (2018). How should minimally important change (MIC) scores for the Patient Oriented Eczema Measure (POEM) be interpreted?: a validation using varied methods. British Journal of Dermatology, 178(5), https://doi.org/10.1111/bjd.16367

Background The Patient Oriented Eczema Measure (POEM), scored 0-28, is the core outcome instrument recommended for measuring patient-reported atopic eczema symptoms in clinical trials. To date, two published studies have broadly concurred that the... Read More about How should minimally important change (MIC) scores for the Patient Oriented Eczema Measure (POEM) be interpreted?: a validation using varied methods.